ALNY in the 13F filings
Alnylam Pharmaceuticals Inc · CUSIP 02043Q107
- Quarter end
- 30 Sep 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 29 Oct 2025
- Managers listing it
- 33
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q2 2025 and Q3 2025; 17 listed it in both
- Shares listed
- 58,415,962
- combined, among listed positions
- Reported value
- $26.6bn
- combined, at the quarter end
Among the 95 comparable managers: 25 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing ALNY in Q3 2025
33 of 33 holders
Largest increases and reductions, by shares
Increases
- Arrowstreet Capital LPexisting position · 1,355,609 shares now+1,185,909
- Fidelity (FMR LLC)existing position · 16,767,625 shares now+961,104
- Two Sigma Advisers LPexisting position · 892,500 shares now+626,400
- AQR Capital Management LLCexisting position · 744,008 shares now+555,759
- MFS Investment Managementnew position · 356,529 shares now+356,529
Reductions
- T. Rowe Price Associates Incexisting position · 1,800,294 shares now-1,344,712
- Dodge & Coxexisting position · 2,321,230 shares now-875,866
- Holocene Advisors LPexisting position · 13,086 shares now-583,730
- Woodline Partners LPexisting position · 91,791 shares now-531,324
- Capital World Investorsexisting position · 16,434,253 shares now-370,754
New positions and exits
New (8)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 4 | $407m | n.a. | n.a. |
| Q3 2013 | 6 | $1.2bn | n.a. | n.a. |
| Q4 2013 | 7 | $1.5bn | n.a. | n.a. |
| Q1 2014 | 8 | $1.6bn | n.a. | n.a. |
| Q2 2014 | 6 | $1.7bn | n.a. | n.a. |
| Q3 2014 | 7 | $2.1bn | n.a. | n.a. |
| Q4 2014 | 6 | $2.2bn | n.a. | n.a. |
| Q1 2015 | 8 | $2.9bn | n.a. | n.a. |
| Q2 2015 | 6 | $3.3bn | n.a. | n.a. |
| Q3 2015 | 5 | $2.1bn | n.a. | n.a. |
| Q4 2015 | 6 | $2.7bn | n.a. | n.a. |
| Q1 2016 | 8 | $2.0bn | n.a. | n.a. |
| Q2 2016 | 7 | $2.0bn | n.a. | n.a. |
| Q3 2016 | 8 | $2.6bn | n.a. | n.a. |
| Q4 2016 | 8 | $1.6bn | n.a. | n.a. |
| Q1 2017 | 9 | $2.2bn | n.a. | n.a. |
| Q2 2017 | 14 | $3.8bn | n.a. | n.a. |
| Q3 2017 | 15 | $5.7bn | n.a. | n.a. |
| Q4 2017 | 14 | $6.3bn | n.a. | n.a. |
| Q1 2018 | 15 | $5.7bn | n.a. | n.a. |
| Q2 2018 | 15 | $4.4bn | n.a. | n.a. |
| Q3 2018 | 14 | $3.9bn | n.a. | n.a. |
| Q4 2018 | 10 | $3.3bn | n.a. | n.a. |
| Q1 2019 | 11 | $4.6bn | n.a. | n.a. |
| Q2 2019 | 16 | $3.8bn | n.a. | n.a. |
| Q3 2019 | 11 | $4.4bn | n.a. | n.a. |
| Q4 2019 | 13 | $6.2bn | n.a. | n.a. |
| Q1 2020 | 12 | $5.7bn | n.a. | n.a. |
| Q2 2020 | 15 | $7.7bn | n.a. | n.a. |
| Q3 2020 | 13 | $7.6bn | n.a. | n.a. |
| Q4 2020 | 13 | $6.5bn | n.a. | n.a. |
| Q1 2021 | 14 | $7.2bn | n.a. | n.a. |
| Q2 2021 | 13 | $8.8bn | n.a. | n.a. |
| Q3 2021 | 14 | $9.7bn | n.a. | n.a. |
| Q4 2021 | 12 | $8.8bn | n.a. | n.a. |
| Q1 2022 | 12 | $8.9bn | n.a. | n.a. |
| Q2 2022 | 13 | $8.1bn | n.a. | n.a. |
| Q3 2022 | 17 | $10.8bn | n.a. | n.a. |
| Q4 2022 | 16 | $13.7bn | n.a. | n.a. |
| Q1 2023 | 19 | $11.5bn | n.a. | n.a. |
| Q2 2023 | 16 | $10.6bn | n.a. | n.a. |
| Q3 2023 | 17 | $9.7bn | n.a. | n.a. |
| Q4 2023 | 15 | $10.0bn | 5 | 9 |
| Q1 2024 | 15 | $7.3bn | 10 | 6 |
| Q2 2024 | 19 | $12.5bn | 12 | 8 |
| Q3 2024 | 18 | $15.1bn | 7 | 11 |
| Q4 2024 | 15 | $12.8bn | 8 | 7 |
| Q1 2025 | 18 | $14.9bn | 11 | 7 |
| Q2 2025 | 22 | $18.3bn | 13 | 10 |
| Q3 2025 | 33 | $26.6bn | 25 | 8 |
| Q4 2025 | 24 | $23.4bn | 15 | 28 |
| Q1 2026 | 22 | $17.9bn | 16 | 18 |
| Q2 2026 | 21 | $15.9bn | 17 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ALNY and LLY →ALNY and JNJ →ALNY and VRTX →Choose a stock to compare with ALNY →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ALNY, latest filings →Back to the 13F Explorer →